Role of Tumor-informed Personalized Circulating Tumor DNA Assay in Informing Recurrence in Patients With Peritoneal Metastases From Colorectal and High-grade Appendix Cancer Undergoing Curative-intent Surgery
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the role of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay in informing recurrence in patients with peritoneal metastases (PM) from colorectal (CRC) and high-grade appendix (HGA) cancer after curative cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). BACKGROUND: Over 50% of patients with CRC/HGA-PM recur after optimal CRS-HIPEC. The limited sensitivity of axial imaging and diagnostic biomarkers is a significant cause of delay in the detection of recurrence and initiation of further therapies. Plasma ctDNA has a promising role in monitoring response to treatment and/or recurrence after primary cancer resection. METHODS: Patients with CRC/HGA-PM who underwent curative CRS-HIPEC and serial postresection ctDNA assessments were included. Patients with rising postoperative ctDNA levels were compared with those with stable, undetectable ctDNA levels. Primary outcomes were the percentage of patients with recurrence and disease-free survival (DFS). Secondary outcomes were overall survival, ctDNA sensitivity, lead time, and performance of ctDNA compared with carcinoembryonic antigen. RESULTS: One hundred thirty serial postresection ctDNA assessments [median 4, interquartile range (IQR), 3 to 5] were performed in 33 patients (n = 13 CRC, n = 20 HGA) who underwent completeness of cytoreduction-0/1 CRS with a median follow-up of 13 months. Of the 19 patients with rising ctDNA levels, 90% recurred versus 21% in the stable ctDNA group (n = 14, < 0.001). Median DFS in the rising ctDNA cohort was 11 months (IQR, 6 to 12) and not reached in the stable ( P = 0.01). A rising ctDNA level was the most significant factor associated with DFS (hazard ratio: 3.67, 95% CI: 1.06-12.66, P = 0.03). The sensitivity and specificity of rising ctDNA levels in predicting recurrence were 85% and 84.6%, respectively. The median ctDNA lead time was 3 months (IQR, 1 to 4). Carcinoembryonic antigen was less sensitive (50%) than ctDNA. CONCLUSIONS: This study supports the clinical validity of serial ctDNA assessment as a strong prognostic biomarker in informing recurrence in patients with CRC/HGA-PM undergoing curative resection. It also holds promises for informing future clinical trial designs and further research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tumor-informed assays, based on the mutations existing in the tumor tissue, enable deep sequencing targeting known mutations and MRD detection, which has been validated across multiple solid tumors.19, 20, 21”
From Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma (2024) · cites this paper as [21]
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840 · cited 1×
“37 We utilized an ultra-sensitive personalized tumor-informed platform to address these pitfalls where whole-exome sequencing was performed upfront on tumor tissue followed by ultra-deep sequencing of a targeted multiplex PCR that included the 16 most prominent mutations in that particular tumor…”
MethodCirculating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,734 · cited 1×
“33 – 36 These technologies have inherent analytical downsides due to their dependence on the presence of speci fi c mutations in the cancer specimen.”
BackgroundPhylogenetic ctDNA analysis depicts early-stage lung cancer evolution
The TRACERx consortium, Abbosh, C., The PEACE consortium, Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le Quesne, J., Moore, D. A., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,874 · cited 1×
“26,28 It becomes critically important in patients with PM where a phenomenon of “ peritoneal-plasma barrier ” is responsible for decreased bioavailability of systemic chemotherapy in peritoneal disease.”
BackgroundLiquid biopsy enters the clinic — implementation issues and future challenges
Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00457-x · Cited by 1,191 · cited 2×
“16,18 Recently, in a multicenter prospective cohort of 130 patients with stage I to III CRC, during surveillance after curative treatment, patients with positive ctDNA after curative surgery were 40 times more likely to experience recurrence than patients with negative ctDNA (HR, 17.5; 95% CI: 5.4…”
BackgroundMethodInfluentialLiquid biopsy and minimal residual disease - latest advances and implications for cure
Pantel, K., & Alix-Panabières, C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0187-3 · Cited by 1,110 · cited 1×
“16,17 These biomarkers have been exploited for their clinical validity in almost every step of cancer management, such as early detection, improved staging, risk strati fi cation, and monitoring response to therapy.”
MethodVerwaal, V. J., Bruin, S., Boot, H., van Slooten, G., & van Tinteren, H. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9966-2 · Cited by 1,033
Reinert, T., Henriksen, T. V., Christensen, E., Sharma, S., Salari, R., Sethi, H., Knudsen, M., Nordentoft, I., Wu, H.-T., Tin, A. S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0528 · Cited by 1,011 · cited 3×
“19,22,26 In addition, ultra-deep sequencing of patient-speci fi c PCR panels can allow a very low detection limit ( 0.01%), thus offering very high sensitivity.”
BackgroundInfluentialTie, J., Cohen, J. D., Wang, Y., Christie, M., Simons, K., Lee, M., Wong, R., Kosmider, S., Ananda, S., McKendrick, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3616 · Cited by 668
Christensen, E., Birkenkamp-Demtröder, K., Sethi, H., Shchegrova, S., Salari, R., Nordentoft, I., Wu, H.-T., Knudsen, M., Lamy, P., Lindskrog, S. V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02052 · Cited by 556 · cited 3×
“19,22,26 In addition, ultra-deep sequencing of patient-speci fi c PCR panels can allow a very low detection limit ( 0.01%), thus offering very high sensitivity.”
BackgroundInfluential
Cited by
Fu, Y., Xu, Y., Liu, W., Zhang, J., Wang, F., Jian, Q., Huang, G., Zou, C., Xie, X., Kim, A. H., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102697 · Cited by 37
Holz, A., Paul, B., Zapf, A., Pantel, K., & Joosse, S. A. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102999 · Cited by 27
Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases
Schultz, K. S., Bansal, V. V., Wach, M. M., Bhutiani, N., Godley, F. A., Wang, J., Waheed, M. T., Buchheit, J. T., Papai, E., Campbell, S. E., et al. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17363-0 · Cited by 23
“97,98 The studies reviewed in KQ2b are not elaborated upon further as none of them described PM-specific results for response to systemic therapies (Supplementary Table 5).”
Self-citationCirculating Tumor DNA and Management of Colorectal Cancer
Krell, M., Llera, B. G., & Brown, Z. J. (2023) · Cancers · doi:10.3390/cancers16010021 · Cited by 21
“Further investigation of RAS status in ctDNA as a useful biomarker of EGFR inhibitors for NeoRAS wild-type metastatic CRC is being explored (C-PROWESS trial) [63].”
BackgroundClinical Applications of Circulating Tumor DNA Profiling in GI Cancers
Battaglin, F., & Lenz, H. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00167 · Cited by 16
“50,51 Finally, a combination of baseline mutational pro fi ling by ctDNA and postsurgical MRD testing by methylation-based ctDNA analysis was shown to predict adjuvant chemotherapy bene fi t and recurrence-free survival in patients with resectable CRC oligometastases in the prospective PRECISION…”
Metadata
- Authors
- Dhiman, A., Kothary, V., Witmer, H. D. D., Bregio, C., Sood, D., Ong, C. T., Polite, B., Eng, O. S., Shergill, A., & Turaga, K. K.
- Affiliations
- University of Chicago Medical Center (US)
- University of Chicago (US)
- Department of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL
- University of California, Irvine (US)
- Corresponding author
- Dhiman, Ankit
- Witmer, Hunter D. D.
- Sood, Divya
- Ong, Cecilia T.
- Turaga, Kiran K.
- ORCID
- Venue
- Annals of Surgery
- Published
- 2023-03-30
- Volume
- 278
- Issue
- 6
- Pages
- 925-931
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W4361273497
- Cited by
- 25
- References
- 39
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 10 · 2023: 2
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Surgery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- circulating tumor DNA, peritoneal carcinomatosis, colorectal cancer, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, recurrence prediction, liquid biopsy, disease-free survival, carcinoembryonic antigen, lead time, treatment response monitoring, metastatic colorectal cancer
- MeSH terms
- Circulating Tumor DNA, Appendiceal Neoplasms, Appendix, Carcinoembryonic Antigen, Combined Modality Therapy, Humans, Hyperthermia, Induced, Chemotherapy, Cancer, Regional Perfusion, Peritoneal Neoplasms, Retrospective Studies, Colorectal Neoplasms, Survival Rate, Cytoreduction Surgical Procedures
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of Tumor-informed Personalized Circulating Tumor DNA Assay in Informing Recurrence in Patients With Peritoneal Metastases From Colorectal and High-grade Appendix Cancer Undergoing Curative-intent Surgery. https://app.cochat.ai/papers/10.1097/sla.0000000000005856
- The paper
- Dhiman, A., Kothary, V., Witmer, H. D. D., Bregio, C., Sood, D., Ong, C. T., Polite, B., Eng, O. S., Shergill, A., & Turaga, K. K. (2023). Role of Tumor-informed Personalized Circulating Tumor DNA Assay in Informing Recurrence in Patients With Peritoneal Metastases From Colorectal and High-grade Appendix Cancer Undergoing Curative-intent Surgery. Annals of Surgery. https://doi.org/10.1097/sla.0000000000005856
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.